Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 October 2026

Six new medicines recommended for approvalEMA’s human medicines committee (CHMP) recommended six medicines for approval at its October 2026 meeting.Rasonque (daraxonrasib)…, CHMP statistics Key figures from the October 2026 CHMP meeting are represented in the graphic below. © European Medicines Agency , CHMP statistics:…, Positive recommendations on new medicines, Foundayo International non-proprietary name (INN) orforglipron Marketing authorisation applicant Eli Lilly Nederland B.V. Therapeutic indication Treatment of…, Rasonque INN daraxonrasib Marketing authorisation applicant Revolution Medicines Netherlands B.V. Therapeutic indication Treatment of metastatic pancreatic…, Yuviwel INN navepegritide Marketing authorisation applicant Ascendis Pharma Growth Disorders A/S Therapeutic indication Treatment of achondroplasia in…, Positive recommendations on new biosimilar medicines, Fovlussea INN ranibizumab Marketing authorisation applicant Accord Healthcare S.L.U. Therapeutic indication Treatment of neovascular (wet) age-related macular…, Neuzafy INN filgrastim Marketing authorisation applicant CuraTeQ Biologics (Malta) Limited Therapeutic indication Treatment of ne...